Last Updated: Oct 21, 2016
- A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Isakoff Steven J, et al. Future oncology (London, England) 2016 10 - Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.
Fernandes Gabriela C, et al. Oncotarget 2016 10 - Moving In and Out of the What-Ifs: The Experiences of Unaffected Women Living in Families Where a Breast Cancer 1 or 2 Genetic Mutation Was Not Found.
Schroeder Dawn et al. Cancer nursing 2016 Oct - Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care.
Graffeo Rossella et al. Breast cancer research and treatment 2016 Oct - Early onset breast cancer in Ashkenazi women carriers of founder BRCA1/2 mutations: beyond 10 years of follow-up.
Dagan E, et al. European journal of cancer care 2016 10 - Implementing Public Health Genomics in Your State: Resources from the CDC Office of Public Health Genomics
Disease: Lynch syndrome|Breast Cancer|Ovarian Cancer; Type: Education; State: Multiple States - Breast and Ovarian Cancer
- Estimation of Heritability for Nine Common Cancers Using Data from Genome-Wide Association Studies in Chinese Population.
Dai Juncheng, et al. International journal of cancer 2016 9 - Psychosocial outcomes and counselee satisfaction following genetic counseling for hereditary breast and ovarian cancer: A patient-reported outcome study.
Oberguggenberger Anne et al. Journal of psychosomatic research 2016 Oct 8939-45 - BRCA Share: A Collection of Clinical BRCA Gene Variants.
Beroud Christophe et al. Human mutation 2016 Sep - Hereditary breast and ovarian cancer: successful systematic implementation of a group approach to genetic counselling.
Benusiglio Patrick R et al. Familial cancer 2016 Sep - Age at menarche and age at natural menopause in East Asian women: a genome-wide association study.
Shi Jiajun, et al. Age (Dordrecht, Netherlands) 2016 9 - Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers.
Zakhour Mae, et al. Gynecologic oncology 2016 9 - The RAD51C exonic splice-site mutations c.404G>C and c.404G>T are associated with familial breast and ovarian cancer.
Neidhardt Guido, et al. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2016 9 - Gene panel sequencing in familial Breast/Ovarian Cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
Kraus Cornelia, et al. International journal of cancer 2016 9
- Human (27)
- Pathogen (0)
- Human (710)
- Pathogen (0)
- Human (160)
- Pathogen (0)
- Huamn (83)
- Pathogen (0)
.png)
No hay comentarios:
Publicar un comentario